by Richard Daverman, PhD
November 14, 2012 -- Hainan Haiyao Co. signed a letter of intent to acquire a 40% stake in SinoMab Bioscience Limited, a company that is headquartered in Hong Kong with offices and manufacturing facilities in Shenzhen. Established in 2001, SinoMab is seeking to discover therapeutic antibodies that treat life-threatening and debilitating diseases. Terms of the proposed transaction were not disclosed. More details....
Stock Symbol: (SHE: 000566)
